Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H24N2O3 |
Molecular Weight | 328.4055 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NN(CCC(O)=O)C(C)=C1CC2=CC(C)=C(O)C3=C2CCC3
InChI
InChIKey=OFUOCIUIWKDKPA-UHFFFAOYSA-N
InChI=1S/C19H24N2O3/c1-11-9-14(15-5-4-6-16(15)19(11)24)10-17-12(2)20-21(13(17)3)8-7-18(22)23/h9,24H,4-8,10H2,1-3H3,(H,22,23)
TRC-150094 is a synthetic compound that displays the capacity to stimulate energy expenditure. TRC-150094 increases whole body energy expenditure, increases mitochondrial fatty acid oxidation (FAO), and reduces abdominal adiposity in rats fed a high-fat diet. TRC-150094 attenuates the progression of hypertension, insulin resistance, dysglycemia, and atherogenic dyslipidemia, factors reported to signify significant cardiovascular (CV) risk amongst viscerally obese dysglycemic subjects. Moreover, at organ level, TRC150094 reduced steatohepatitis, reduced progression of nephropathy, and preserved cardiac contractile function. Pharmacological profile of TRC-150094 may constitute a promising new class of molecules that may have a potential beneficial therapeutic approach for the treatment of nontraditional CV risk factors and may reduce residual risk in viscerally obese dysglycemic patients. Moreover, the observed metabolic and functional effects on skeletal muscle suggest that TRC-150094 as a therapy may help to facilitate adherence to prescribed exercise, which would remain the mainstay along with diet control in such patients. Simultaneous systemic administration of TRC-150094 to rats receiving an high-fat diet results in a reduction in fat accumulation within the liver and a marked reduction in adipose tissue mass. TRC-150094 is in phase-III clinical trials for the treatment of diabetes mellitus, hypertension and dyslipidaemias (adjunctive treatment) in India.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats. | 2011 Jan 6 |
|
The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial. | 2014 |
|
Thyroid hormone analogues and derivatives: Actions in fatty liver. | 2014 Mar 27 |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C184893
Created by
admin on Sat Dec 16 08:03:21 GMT 2023 , Edited by admin on Sat Dec 16 08:03:21 GMT 2023
|
PRIMARY | |||
|
11824
Created by
admin on Sat Dec 16 08:03:21 GMT 2023 , Edited by admin on Sat Dec 16 08:03:21 GMT 2023
|
PRIMARY | |||
|
25125529
Created by
admin on Sat Dec 16 08:03:21 GMT 2023 , Edited by admin on Sat Dec 16 08:03:21 GMT 2023
|
PRIMARY | |||
|
300000039096
Created by
admin on Sat Dec 16 08:03:21 GMT 2023 , Edited by admin on Sat Dec 16 08:03:21 GMT 2023
|
PRIMARY | |||
|
TRC-150094
Created by
admin on Sat Dec 16 08:03:21 GMT 2023 , Edited by admin on Sat Dec 16 08:03:21 GMT 2023
|
PRIMARY | |||
|
DTXSID70148862
Created by
admin on Sat Dec 16 08:03:21 GMT 2023 , Edited by admin on Sat Dec 16 08:03:21 GMT 2023
|
PRIMARY | |||
|
1092551-88-6
Created by
admin on Sat Dec 16 08:03:21 GMT 2023 , Edited by admin on Sat Dec 16 08:03:21 GMT 2023
|
PRIMARY | |||
|
B93608MTGW
Created by
admin on Sat Dec 16 08:03:21 GMT 2023 , Edited by admin on Sat Dec 16 08:03:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY